Seres Therapeutics (NASDAQ:MCRB) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

MCRB has been the topic of several other research reports. BidaskClub downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Bank of America downgraded shares of Seres Therapeutics from a “neutral” rating to an “underperform” rating in a report on Friday, August 3rd. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Wednesday, May 16th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $17.25.

Shares of NASDAQ:MCRB opened at $8.66 on Tuesday. The company has a current ratio of 2.76, a quick ratio of 2.76 and a debt-to-equity ratio of -0.61. Seres Therapeutics has a 1-year low of $6.65 and a 1-year high of $17.42. The company has a market cap of $358.19 million, a price-to-earnings ratio of -3.92 and a beta of 0.53.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.01. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%. The business had revenue of $4.61 million for the quarter, compared to the consensus estimate of $5.22 million. equities research analysts predict that Seres Therapeutics will post -2.45 EPS for the current fiscal year.

In related news, CEO Roger Pomerantz sold 40,057 shares of the company’s stock in a transaction on Friday, June 22nd. The shares were sold at an average price of $9.36, for a total transaction of $374,933.52. Following the sale, the chief executive officer now owns 297,812 shares of the company’s stock, valued at $2,787,520.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $8.57, for a total transaction of $122,371.03. Following the sale, the insider now directly owns 170,206 shares in the company, valued at approximately $1,458,665.42. The disclosure for this sale can be found here. Insiders sold 191,048 shares of company stock worth $1,736,213 in the last three months. Insiders own 37.10% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its stake in Seres Therapeutics by 107.2% during the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 15,097 shares in the last quarter. Spark Investment Management LLC raised its stake in Seres Therapeutics by 56.8% during the first quarter. Spark Investment Management LLC now owns 79,500 shares of the biotechnology company’s stock valued at $583,000 after purchasing an additional 28,800 shares in the last quarter. Federated Investors Inc. PA raised its stake in Seres Therapeutics by 18.1% during the first quarter. Federated Investors Inc. PA now owns 1,766,681 shares of the biotechnology company’s stock valued at $12,968,000 after purchasing an additional 270,224 shares in the last quarter. Alps Advisors Inc. raised its stake in Seres Therapeutics by 21.0% during the first quarter. Alps Advisors Inc. now owns 54,359 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 9,448 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Seres Therapeutics by 35.7% during the second quarter. ARK Investment Management LLC now owns 3,266,428 shares of the biotechnology company’s stock valued at $28,091,000 after purchasing an additional 859,705 shares in the last quarter. 78.04% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Read More: How to Invest in Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.